机译:AZD9291的结构基础EGFR T790M的选择性
Peking Univ Hlth Sci Ctr Dept Biochem &
Biophys Beijing 100191 Peoples R China;
DE Shaw Res New York NY 10036 USA;
Qingdao Univ Coll Med Inst Translat Med Affiliated Hosp Qingdao 266021 Peoples R China;
Peking Univ Hlth Sci Ctr Dept Biochem &
Biophys Beijing 100191 Peoples R China;
Peking Univ Hlth Sci Ctr Dept Biochem &
Biophys Beijing 100191 Peoples R China;
DE Shaw Res New York NY 10036 USA;
Peking Univ Hlth Sci Ctr Dept Biochem &
Biophys Beijing 100191 Peoples R China;
DE Shaw Res New York NY 10036 USA;
Harvard Med Sch Dept Biol Chem &
Mol Pharmacol Boston MA 02115 USA;
Hongyun Biotech Co Ltd Nanjing Jiangsu Peoples R China;
DE Shaw Res New York NY 10036 USA;
DE Shaw Res New York NY 10036 USA;
Peking Univ Hlth Sci Ctr Dept Biochem &
Biophys Beijing 100191 Peoples R China;
机译:AZD9291的结构基础EGFR T790M的选择性
机译:发现有效和选择性的EGFR抑制剂(AZD9291)的敏化和T790M抗性突变,都保留了野生型的受体。
机译:N5取代的6,7-二氧-6,7-二氢蝶啶类化合物作为针对L858R / T790M耐药突变的有效和选择性表皮生长因子受体(EGFR)抑制剂的发现和结构优化
机译:整合素与细胞外基质的选择性基础
机译:通过ADAR2进行RNA编辑和位点选择性的结构基础
机译:获得性EGFR C797S介导携带EGFR T790M的晚期非小细胞肺癌对AZD9291的耐药性
机译:AZD9291的结构基础EGFR T790M的选择性
机译:药物设计中EGFR二聚化的结构基础